The GOSPEL 1 Trial

Partnering with general practitioners to optimise survivorship for patients with lymphoma: A Phase 2 randomised controlled trial

Project dates:
Commenced: 2020
Completion Due: 2023

Despite good survival outcomes for people diagnosed with, and treated for lymphomas, these people require quality survivorship care. This includes:

  • monitoring for cancer recurrence
  • surveillance for secondary or new primary cancers
  • management of a range of long-term-bio-psycho-social effects from their diagnosis and cancer treatments.

These health concerns highlight the need for a well-integrated, patient-centred model of care for cancer survivors following the completion of cancer treatment.

This prospective, pragmatic randomised controlled trial aims to test the feasibility of the GOSPEL 1 intervention compared to usual care involving Haematologists and General Practitioners for lymphoma shared follow-up survivorship care. Outcomes measured include a range of patient-reported outcomes, safety indicators such as hospital admission and unscheduled lymphoma clinic visits, and process outcomes including the intervention fidelity and economic indicators.

Project outcomes:
This study seeks to demonstrate the feasibility, utility, usefulness, and preliminary efficacy of the new model of shared care between specialists and primary care which could influence lymphoma survivorship follow-up care for cancer survivors.


Funding / Grants

  • Health Innovation, Investment and Research Office (HIIRO) Queensland Advancing Clinical Research Fellowships

Chief Investigators